Respectfully I do not. At this point in time .... maybe. All that has transpired over the past decade I am not about to cheer management. Starting with Woodford. That said, there is finally confirmation of the tissue agnostic path that I have wanted and invested. Partnerships, Eden and Direct making the product more viable and less expensive is only more fuel to the fire. As the SP climbs I may overlook some of the incredible missteps. Not a pleasant journey but light is appearing at the tunnel's end.
Market Data 
Markets 
AI
